Unichem Lab shares rise over 7 pc after USFDA approval for hypertension drug

Image
Press Trust of India New Delhi
Last Updated : Nov 25 2019 | 11:45 AM IST

Unichem Laboratories shares on Monday surged over 7 per cent after the company got approval from the US health regulator for Atenolol tablets.

Shares of the drug firm gained 7.04 per cent to trade at Rs 164 on the BSE.

On the NSE, the stock was up 7.22 per cent at Rs 164.

Unichem Laboratories on Friday said it has received approval from the USFDA to market its generic Atenolol tablets used for the treatment of hypertension.

"Unichem Laboratories Ltd has received ANDA approval for its Atenolol tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENORMIN (Atenolol) Tablets, 25 mg, 50 mg, and 100 mg, of Alvogen Malta Operations Ltd," the company said in a BSE filing.

The filing came in the late evening on Friday.

The product will be commercialised from the company's Ghaziabad plant, it added.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 25 2019 | 11:45 AM IST

Next Story